- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01432444
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole (ARRIVE US)
April 20, 2015 updated by: Otsuka Pharmaceutical Development & Commercialization, Inc.
Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months and IM Depot Aripiprazole for 6 Months, Respectively, in a Naturalistic Community Setting
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Nonadherence to antipsychotic medications remains a frequent cause of relapse among patients with schizophrenia, increasing hospitalization rates, hospitalization days, and hospitalization costs.
Among hospitalized adults, schizophrenia is the fourth most commonly diagnosed illness and has the seventh longest mean duration of hospital stay in the US.
Frequent relapses and hospitalization can affect quality of life in these patients.
Long-acting injections (intramuscular depot) antipsychotic medication is a means to treatment adherence and increased quality of life for patients with schizophrenia.
Study Type
Interventional
Enrollment (Actual)
493
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Penticton, British Columbia, Canada, V2A 4M4
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2E2
-
-
Ontario
-
Brampton, Ontario, Canada, L6T 0G1
-
Chatham, Ontario, Canada, N7M 5L9
-
-
Quebec
-
Montreal, Quebec, Canada, H3A1A1
-
-
-
-
Alabama
-
Dothan, Alabama, United States, 36305
-
-
Arizona
-
Tucson, Arizona, United States, 85719
-
-
Arkansas
-
Fayetteville, Arkansas, United States, 72703
-
Little Rock, Arkansas, United States, 72201
-
-
California
-
Anaheim, California, United States, 92804
-
Anaheim, California, United States, 92801
-
Bellflower, California, United States, 90706
-
Carson, California, United States, 90746
-
Costa Mesa, California, United States, 92626
-
Downey, California, United States, 90241
-
Escondido, California, United States, 92025
-
Garden Grove, California, United States, 92845
-
Glendale, California, United States, 91206
-
Glendale, California, United States, 91204
-
Los Angeles, California, United States
-
National City, California, United States, 91950
-
Norwalk, California, United States, 60950
-
Oakland, California, United States, 94612
-
Oceanside, California, United States, 92056
-
Orange, California, United States
-
Palo Alto, California, United States, 94304
-
Paramount, California, United States, 92626
-
Pasadena, California, United States, 91106-2500
-
Riverside, California, United States, 92506
-
San Diego, California, United States, 92108
-
San Diego, California, United States, 92121
-
San Diego, California, United States, 92117
-
San Francisco, California, United States, 94104
-
Santa Ana, California, United States, 92705
-
Torrance, California, United States, 90502
-
-
Connecticut
-
Middletown, Connecticut, United States, 06457
-
New Brittain, Connecticut, United States, 06050
-
Norwalk, Connecticut, United States, 06851
-
-
Florida
-
Boynton Beach, Florida, United States, 33435
-
Coral Gables, Florida, United States, 33134
-
Doral, Florida, United States, 33172
-
Hialeah, Florida, United States, 33014
-
Jacksonville Beach, Florida, United States, 32250
-
Miami, Florida, United States, 33136
-
Miami, Florida, United States, 33144
-
Miami, Florida, United States, 33155
-
Miami, Florida, United States, 33125
-
Miami, Florida, United States, 33135
-
Miami, Florida, United States, 33122
-
Oakland Park, Florida, United States, 33334
-
Orange City, Florida, United States, 32763
-
Orlando, Florida, United States, 32803
-
Plantation, Florida, United States, 33317
-
South Miami, Florida, United States, 33143
-
St. Augustine, Florida, United States, 32086
-
St. Petersburg, Florida, United States, 33716
-
Tampa, Florida, United States, 33613
-
Tampa, Florida, United States, 33559
-
-
Georgia
-
Atlanta, Georgia, United States, 30301
-
Decatur, Georgia, United States, 30030
-
Marietta, Georgia, United States, 30062
-
-
Illinois
-
Chicago, Illinois, United States, 60611-4296
-
Joliet, Illinois, United States, 60435
-
Naperville, Illinois, United States, 60563
-
-
Indiana
-
South Bend, Indiana, United States, 46617
-
-
Kansas
-
Topeka, Kansas, United States, 66606
-
Witchita, Kansas, United States, 67207
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
-
Brockton, Massachusetts, United States, 02301
-
Newton, Massachusetts, United States, 02458
-
-
Michigan
-
Bloomfield Hills, Michigan, United States, 48302
-
Grand Rapids, Michigan, United States, 49503
-
Paw Paw, Michigan, United States, 49079
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55454
-
-
Missouri
-
Creve Coeur, Missouri, United States, 63141
-
Kansas City, Missouri, United States, 64114
-
Kansas City, Missouri, United States, 64108
-
St. Charles, Missouri, United States, 63301
-
St. Louis, Missouri, United States, 63128
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68526
-
North Platte, Nebraska, United States, 69101
-
-
Nevada
-
Sparks, Nevada, United States, 89434
-
-
New Hampshire
-
Nashua, New Hampshire, United States, 03060
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
-
-
New York
-
Amherst, New York, United States, 14226
-
Brooklyn, New York, United States, 11203
-
Brooklyn, New York, United States, 11241
-
Brooklyn, New York, United States, 11206
-
Buffalo, New York, United States, 14215
-
New York, New York, United States, 10065
-
New York, New York, United States, 10027
-
New York, New York, United States, 10128
-
Rochester, New York, United States, 14618
-
Rochester, New York, United States, 14615
-
Syracuse, New York, United States, 13202
-
Wards Island, New York, United States, 10035
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
-
Durham, North Carolina, United States, 27704
-
-
Ohio
-
Canton, Ohio, United States, 44718
-
Centennial, Ohio, United States, 80112
-
Garfield Heights, Ohio, United States, 44125
-
Mason, Ohio, United States, 45040
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
Oklahoma City, Oklahoma, United States, 73112
-
-
Pennsylvania
-
McMurray, Pennsylvania, United States, 15317
-
Phoenixville, Pennsylvania, United States, 19460
-
Scranton, Pennsylvania, United States, 18503
-
Sellersville, Pennsylvania, United States, 18960
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
-
-
Tennessee
-
Franklin, Tennessee, United States, 37067
-
Memphis, Tennessee, United States, 38119
-
-
Texas
-
Austin, Texas, United States, 78731
-
Dallas, Texas, United States, 75231
-
Dallas, Texas, United States, 75390-8828
-
Houston, Texas, United States, 77054
-
Houston, Texas, United States, 77081
-
San Antonio, Texas, United States, 78229
-
Wharton, Texas, United States, 77488
-
-
Utah
-
Salt Lake City, Utah, United States, 84105
-
-
Washington
-
Bellevue, Washington, United States, 98007
-
Bothell, Washington, United States, 98011
-
Kirkland, Washington, United States, 98033
-
Spokane, Washington, United States, 99204
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects who are able to provide written informed consent. If the IRB requires consent by a legally acceptable representative in addition to the subject, all required consents must be obtained prior to any protocol-required procedure.
- Male and female subjects 18 to 65 years of age, inclusive.
- Current diagnosis of schizophrenia as defined by DSM-IV-TR criteria and a history of the illness for at least 1 year (12 months).
- Subjects who in the investigator's judgment would benefit from extended treatment with a long-acting injectable formulation.
- Subjects who have at least 1 inpatient psychiatric hospitalization in the 4 years (48 months) prior to screening, but have been managed as outpatients for the 4 weeks prior entering the study.
- Subjects must have been on oral antipsychotic treatment for the full 7 months prior to the screening phase.
- Subjects who have shown response to previous antipsychotic treatment.
- Subjects who understand the nature of the trial and are able to follow the protocol requirements.
Exclusion Criteria:
- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated), or have been incarcerated in the past 7 months for any reason must not be enrolled into this trial.
- Subjects who may require potent CYP2D6 or CYP3A4 inhibitors or CYP3A4 inducers during the trial.
- Any subject who requires or may need any other antipsychotic medications during the course of the trial, other than allowed rescue medication.
- Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones.
- Subjects with a history of hypersensitivity to antipsychotic agents.
- Subjects deemed intolerant of receiving injectable treatment.
- Subjects who have received electroconvulsive therapy within the last 7 months prior to screening.
- Subjects with a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia as assessed by the investigator.
- Subjects with a current DSM-IV-TR diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
- Subjects requiring hospitalization for any psychiatric reason during the 4 weeks prior to signing the ICF or during the screening period.
- Subjects without at least 1 inpatient psychiatric hospitalization in the last 4 years (48 months) prior to screening.
- Subjects who have met DSM-IV-TR criteria for any significant substance use disorder within 3 months prior to screening.
- Subjects who are considered treatment-resistant to antipsychotic medication other than clozapine.
- Treatment with long-acting injectable antipsychotics in which the last dose was within 7 months prior to screening.
- Subjects who have not been treated with oral antipsychotics for 7 months prior to screening.
- Subjects who have a significant risk of committing suicide
- Subjects who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial.
- Females who are pregnant or lactating, sexually active males and females who will not commit to utilizing birth control during the trial and for up to 180 days following the trial.
- Abnormal laboratory or physical examination results indicating a condition which may interfere with the results of the study or pose a safety risk to the subject.
- Subjects who have previously enrolled in an aripiprazole IM depot clinical study, except for subjects entering this trial from the Canadian 31-11-284 trial.
- Subjects who have participated in any clinical trial with an investigational agent within the past 30 days.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OPC-14597
Aripiprazole IM depot injection 300 mg or 400 mg.
|
400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg. Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Inpatient Psychiatric Hospitalization for Retrospective Period (Months 4-6) and Prospective Period (Months 4-6).
Time Frame: Retrospective period Months 4-6; Prospective period Months 4-6
|
The comparison of inpatient psychiatric hospitalization rates (proportion of patients with ≥ inpatient psychiatric hospitalizations) between the retrospective period months 4-6 (Weeks-12 to -24) while on oral standard of care antipsychotic treatment and the prospective period Phase B months 4-6 (Weeks 12 to 24) after the switch to aripiprazole IM depot.
Open-label Aripiprazole IM Depot Treatment Phase 3-month Completer sample comprised of all participants who entered open-label aripiprazole IM depot treatment Phase and completed at least 3 months of treatment.
This sample was used for the primary endpoint analysis (N=336).
|
Retrospective period Months 4-6; Prospective period Months 4-6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in PANSS (Positive and Negative Syndrome Scale) Total Score.
Time Frame: Baseline to Week 24
|
The PANSS consists of three subscales with a total of 30 symptom constructs.
For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms).
The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs.
The PANSS total score ranges from 30 to 210.
|
Baseline to Week 24
|
Change From Baseline in PANSS Positive Subscale Score.
Time Frame: Baseline to Week 24
|
The PANSS consists of three subscales with a total of 30 symptom constructs.
For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms).
The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs.
The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity suspiciousness/ persecution, and hostility.
The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
|
Baseline to Week 24
|
Change From Baseline in PANSS Negative Subscale Score.
Time Frame: Baseline to Week 24
|
The PANSS consists of three subscales with a total of 30 symptom constructs.
For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms).
The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs.
The 7 negative symptom constructs are blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking.
The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
|
Baseline to Week 24
|
Change From Baseline in Clinical Global Impression-Severity Score (CGI-S).
Time Frame: Baseline to Week 24
|
The severity of illness for each participant were rated using the CGI-S scale.
To assess CGI-S, study physician were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?"
Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients.
|
Baseline to Week 24
|
Mean Clinical Global Impression-Improvement Score (CGI-I) by Week.
Time Frame: Week 4, 12 and 24
|
The efficacy of trial medication was rated for each participant using the CGI-I scale.
The study physician would rate the participants total improvement whether or not it was entirely due to drug treatment.
All responses were compared to the participants condition at Baseline of the appropriate phase.
The CGI-I during Phase B were assessed relative to the participants condition at the Phase B Baseline visit.
Response choices included: 0 = not assessed; 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse.
|
Week 4, 12 and 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Kevin Cox, MD, Kevin.TC-Cox@otsuka-us.com
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Peters-Strickland T, Zhao C, Perry PP, Eramo A, Salzman PM, McQuade RD, Johnson BR, Sanchez R. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS Spectr. 2016 Dec;21(6):460-465. doi: 10.1017/S1092852916000365. Epub 2016 Aug 17.
- Kane JM, Zhao C, Johnson BR, Baker RA, Eramo A, McQuade RD, Duca AR, Sanchez R, Peters-Strickland T. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ. 2015 Feb;18(2):145-54. doi: 10.3111/13696998.2014.979936. Epub 2014 Nov 10.
- Kane JM, Sanchez R, Zhao J, Duca AR, Johnson BR, McQuade RD, Eramo A, Baker RA, Peters-Strickland T. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ. 2013 Jul;16(7):917-25. doi: 10.3111/13696998.2013.804411. Epub 2013 May 28.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Actual)
December 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
September 9, 2011
First Submitted That Met QC Criteria
September 12, 2011
First Posted (Estimate)
September 13, 2011
Study Record Updates
Last Update Posted (Estimate)
May 7, 2015
Last Update Submitted That Met QC Criteria
April 20, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Aripiprazole
Other Study ID Numbers
- 31-11-283
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Aripiprazole (Abilify®) IM Depot Injection
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedSchizophreniaBelgium, Bulgaria, Canada
-
Otsuka Beijing Research InstituteCompleted
-
Otsuka Beijing Research InstituteCompleted
-
Otsuka Beijing Research InstituteCompleted
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States
-
H. Lundbeck A/SOtsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompletedBipolar I DisorderUnited States, Taiwan, Romania, Korea, Republic of, Japan, Poland, Canada
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaKorea, Republic of, United States, Estonia, Italy, Hungary, Bulgaria, Croatia, France, Poland, Thailand, Puerto Rico, Chile, South Africa, Austria, Belgium
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States, Argentina, Bulgaria, India, Malaysia, Mexico, Philippines, Romania, Russian Federation, Serbia, Slovakia, Taiwan